PCI 3.06.26
Wallonia

Current Edition

Current Features

Biomanufacturing

Mastering ADC Bioconjugation: From DAR Control to Efficient Free Payload Removal

Continue reading

Upcoming Events

Auto Draft
Elrig
Auto Draft
CPHI
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Optimisation of a Quality Control Method for Identity, Purity and Quantity for Oligonucleotide Therapeutics

Thomas Franz, Steven A. Watt, Rita Beel, Lejon Martens

Full-length messenger ribonucleic acid (mRNA) based vaccines came into fame in the aftermath of the 2019 coronavirus outbreak, which has rapidly developed into a global pandemic. The two mRNA vaccines developed by Moderna and BioNTech/ Pfizer were the first mRNA therapeutics to be granted an Emergency Use Authorization by the EMA and US-FDA and proved to be safe and efficacious treatments against COVID infection. In this application note, A&M STABTEST wants to present an LC MS-based platform method for the determination of the identity, purity and quantity of oligonucleotides and which parameters are worth investigating to optimise the method in terms of chromatographic resolution of impurities.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience